Abstract
Abstract Background Polycystic ovary syndrome (PCOS) is a common disorder in the childbearing period. Apelin is a regulator of glucose metabolism and is associated with insulin resistance (IR). Metformin is used in PCOS, but its effects on serum apelin in PCOS patients are unknown. Aim To compare serum apelin levels in lean and obese PCOS women and to evaluate the effects of metformin treatment on serum apelin levels, clinical and metabolic parameters, and hormone profile in these patients. Methods A prospective interventional study involving 59 PCOS patients (38 obese and 21 lean) was conducted. Body mass index (BMI), serum apelin, glucose, insulin, FSH, LH and testosterone levels were measured, and HOMA-IR was calculated before and after six months of metformin treatment. Results Significantly higher BMI and serum apelin (P Conclusion Serum apelin levels were higher in obese than lean PCOS patients. Metformin treatment improved insulin sensitivity and decreased serum apelin, LH and testosterone levels in both groups; lean PCOS patients showed better response to metformin treatment.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call